<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03691870</url>
  </required_header>
  <id_info>
    <org_study_id>18.118</org_study_id>
    <nct_id>NCT03691870</nct_id>
  </id_info>
  <brief_title>Transvenous Approach for the Treatment of Cerebral Arteriovenous Malformations</brief_title>
  <acronym>TATAM</acronym>
  <official_title>Transvenous Approach for the Treatment of Cerebral Arteriovenous Malformations (TATAM): A Randomized Controlled Trial and Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A new endovascular route for the treatment of brain AVMs may be possible in some cases:
      Trans-Venous Embolization (TVE). The technique uses microcatheters to navigate to the
      draining veins of AVM, to reach and then fill the AVM nidus retrogradely with liquid embolic
      agents until the lesion is occluded. This technique has the potential to improve on some of
      the problems with the arterial approach to AVM embolization, such as a low overall occlusion
      rate. However, by occluding the vein first, and filling the lesion with the embolic agent in
      a retrograde fashion, the method transgresses a widely held dogma in the surgical or
      endovascular treatment of AVMs: to preserve the draining vein until all afferent vessels have
      been occluded. Nevertheless, the initial case series have shown promising results, with high
      occlusion rates, and few technical complications.

      The method is increasingly used in an increasing number of centers, but there is currently no
      research protocol to guide the use of this promising but still experimental treatment in a
      prudent fashion. Care trials can be designed to offer such an experimental treatment, taking
      into account the best medical interests of patients, in the presence of rapidly evolving
      indications and techniques.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2, 2018</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Angiographic evidence of residual AVM at time of confirmatory catheter angiography.</measure>
    <time_frame>3 months +/- 1 month following embolization</time_frame>
    <description>Angiographic evidence of residual AVM at time of confirmatory catheter angiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Failure to safely and effectively position the embolization microcatheter.</measure>
    <time_frame>within day of procedure</time_frame>
    <description>Failure to reach a safe and effective microcatheter position for embolization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any procedural complication leading to transient new neurological deficit.</measure>
    <time_frame>&lt;5 days</time_frame>
    <description>Any procedural complication leading to transient new neurological deficit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any procedural complication leading to new neurological deficit.</measure>
    <time_frame>≥5 days</time_frame>
    <description>Any procedural complication leading to new neurological deficit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any treatment-related complication that prolongs hospitalization by ≥5 days.</measure>
    <time_frame>Within one week</time_frame>
    <description>Any treatment-related complication that prolongs hospitalization by ≥5 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new ischemia following treatment (Brain MR imaging prior to discharge with diffusion sequences).</measure>
    <time_frame>within 5 days post procedure</time_frame>
    <description>Incidence of new ischemia following treatment (Brain MR imaging prior to discharge with diffusion sequences).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization (days).</measure>
    <time_frame>≥5 days</time_frame>
    <description>Length of hospitalization (days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient discharge to a location that is not his/her home.</measure>
    <time_frame>through to 3 (+/- 1) months follow-up</time_frame>
    <description>Discharge to location other than home.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRS at discharge and 3(+/-1) months.</measure>
    <time_frame>through to 3 (+/- 1) months follow-up</time_frame>
    <description>mRS at discharge and 3(+/-1) months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new admission to hospital during follow-up.</measure>
    <time_frame>Within 3 +/- months post final treatment</time_frame>
    <description>Incidence of new admission to hospital during follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of intracranial hemorrhage during follow-up.</measure>
    <time_frame>Within 3 +/- months post final treatment</time_frame>
    <description>Incidence of intracranial hemorrhage during follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of residual AVM on confirmatory catheter angiography at 3(+/-1) months post-treatment.</measure>
    <time_frame>at 3(+/-1) months post-treatment.</time_frame>
    <description>Incidence of residual AVM on confirmatory catheter angiography at 3(+/-1) months post-treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Arteriovenous Malformations, Cerebral</condition>
  <condition>Unruptured Brain Arteriovenous Malformation</condition>
  <condition>Ruptured Brain Arteriovenous Malformation</condition>
  <arm_group>
    <arm_group_label>standard Trans-Arterial Embolization (TAE)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The standard TAE, without TVE, is used in patient allocated standard treatment.
The arterial approach will consist of at least one attempted catheterization for trans-arterial injection of liquid embolic.
Patients incompletely treated at the time of the final embolization procedure are adjudicated a failure to reach the primary outcome and can be treated using alternative standard options (including surgery, radiation therapy, conservative management). In addition, patients of the control group can also be offered TVE, if still feasible, once the TAE has been adjudicated to be a failure.
If the operator deems, on the table, for a trans-arterial injection to be too dangerous, no arterial injection is necessary. Treatment, where indicated, can be completed through other means.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trans-Venous Embolization (TVE) (+/- Arterial) strategy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The experimental treatment is an attempt to completely occlude the AVM using venous catheterization and retrograde EVOH injection during the final session. TAE can be performed to prepare for final TVE during the same or one previous preparatory session, or TAE can be used to rescue an incomplete TVE. In some patients, balloon catheterization is used trans-arterially to assist TVE.
It will be permissible to perform more than one treatment session when deemed necessary (occasionally to treat an AVM through the trans-venous route requires a two-stage approach, with a single trans-arterial attempt to decrease AVM filling prior to the definitive trans-venous approach, and this will be permitted).
The trans-venous strategy will consist of at least one transvenous injection of ethyl vinyl alcohol (EVOH), with the choice of delivery microcatheters and other technical details left to the individual operator's discretion).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard Trans-Arterial Embolization (TAE)</intervention_name>
    <description>The standard TAE, without TVE, is used in patient allocated standard treatment. The arterial approach will consist of at least one attempted catheterization for trans-arterial injection of liquid embolic.
If the operator deems, on the table, for a trans-arterial injection to be too dangerous, no arterial injection is necessary. Treatment, where indicated, can be completed through other means.</description>
    <arm_group_label>standard Trans-Arterial Embolization (TAE)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Trans-Venous Embolization (TVE)</intervention_name>
    <description>The experimental treatment is an attempt to completely occlude the AVM using venous catheterization and retrograde EVOH injection during the final session.
The trans-venous strategy will consist of at least one transvenous injection of ethyl vinyl alcohol (EVOH), with the choice of delivery microcatheters and other technical details left to the individual operator's discretion.</description>
    <arm_group_label>Trans-Venous Embolization (TVE) (+/- Arterial) strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient harboring a brain AVM (ruptured or unruptured) in whom TVE is considered a
             promising but yet unproven therapeutic option by the participating clinicians can be
             submitted to the Case Selection Committee.

          -  Patients must be in stable, non-urgent clinical condition, with the acute phase of the
             AVM rupture resolved (where applicable).

          -  Case must be approved by the CSC.

        Notes on potentially suitable cases:

          1. Current indications may include (but are NOT restricted to) brain AVMs with a small &lt;3
             cm nidus (or small residual nidus), with a single draining vein, and for which
             curative treatment can be attained with one or at most two treatment sessions.

          2. Physicians are not required to submit cases prior to any or all treatment; a case can
             be submitted to the CSC for consideration after previous treatments (including
             previous arterial embolization sessions) have been performed. The timing of the
             submission of the case will be left to individual operators. Previously treated AVMs
             (by any other modality: embolization/surgical resection/radiosurgery) are not excluded
             from TATAM.

        Exclusion Criteria:

          -  Absolute contra-indication to endovascular treatment or anesthesia.

          -  Inability to obtain informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean Raymond, MD</last_name>
    <phone>514-890-8000</phone>
    <phone_ext>27235</phone_ext>
    <email>jraymond.nri@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tim Darsaut, MD</last_name>
    <phone>780-407-1440</phone>
    <email>tdarsaut@ualberta.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim Darsaut, MD</last_name>
      <email>tdarsaut@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Tim Darsaut, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 0C1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guylaine Gevry</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>27235</phone_ext>
      <email>guylaine.gevry.chum@ssss.gouv.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Ruby Klink, PhD</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>26359</phone_ext>
      <email>Ruby.Klink@crchum.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Jean Raymond, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Roy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alain Weill, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier régional universitaire de Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Christophe Gentric, MD</last_name>
      <email>jean-christophe.gentric@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Christophe Gentric, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamel Boubagra, MD</last_name>
      <email>KBoubagra@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Kamel Boubagra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier Heck, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emanuelle Lorian</last_name>
      <email>emmanuelle.lorian@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Charbel Mounayer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Forndation Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Piotin, MD</last_name>
      <email>mpiotin@for.paris</email>
    </contact>
    <investigator>
      <last_name>Michel Piotin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Rouen Normandie</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chrysanthi Papagiannaki, MD</last_name>
      <email>C.Papagiannaki@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Chrysanthi Papagiannaki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de la Réunion</name>
      <address>
        <city>Saint-Paul</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Bintner, MD</last_name>
      <phone>02 62 35 90 86</phone>
      <email>marc.bintner@chu-reunion.fr</email>
    </contact>
    <investigator>
      <last_name>Marc Bintner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>van Beijnum J, van der Worp HB, Buis DR, Al-Shahi Salman R, Kappelle LJ, Rinkel GJ, van der Sprenkel JW, Vandertop WP, Algra A, Klijn CJ. Treatment of brain arteriovenous malformations: a systematic review and meta-analysis. JAMA. 2011 Nov 9;306(18):2011-9. doi: 10.1001/jama.2011.1632. Review.</citation>
    <PMID>22068993</PMID>
  </reference>
  <reference>
    <citation>Iosif C, Mendes GA, Saleme S, Ponomarjova S, Silveira EP, Caire F, Mounayer C. Endovascular transvenous cure for ruptured brain arteriovenous malformations in complex cases with high Spetzler-Martin grades. J Neurosurg. 2015 May;122(5):1229-38. doi: 10.3171/2014.9.JNS141714. Epub 2015 Mar 20.</citation>
    <PMID>25794338</PMID>
  </reference>
  <reference>
    <citation>Kessler I, Riva R, Ruggiero M, Manisor M, Al-Khawaldeh M, Mounayer C. Successful transvenous embolization of brain arteriovenous malformations using Onyx in five consecutive patients. Neurosurgery. 2011 Jul;69(1):184-93; discussion 193. doi: 10.1227/NEU.0b013e318212bb34.</citation>
    <PMID>21346657</PMID>
  </reference>
  <reference>
    <citation>Mendes GAC, Kalani MYS, Iosif C, Lucena AF, Carvalho R, Saleme S, Mounayer C. Transvenous Curative Embolization of Cerebral Arteriovenous Malformations: A Prospective Cohort Study. Neurosurgery. 2018 Nov 1;83(5):957-964. doi: 10.1093/neuros/nyx581.</citation>
    <PMID>29281075</PMID>
  </reference>
  <reference>
    <citation>Zhang G, Zhu S, Wu P, Xu S, Shi H. The transvenous pressure cooker technique: A treatment for brain arteriovenous malformations. Interv Neuroradiol. 2017 Apr;23(2):194-199. doi: 10.1177/1591019916682357. Epub 2016 Dec 5.</citation>
    <PMID>27913800</PMID>
  </reference>
  <reference>
    <citation>Raymond J, Darsaut TE, Altman DG. Pragmatic trials can be designed as optimal medical care: principles and methods of care trials. J Clin Epidemiol. 2014 Oct;67(10):1150-6. doi: 10.1016/j.jclinepi.2014.04.010. Epub 2014 Jul 16.</citation>
    <PMID>25042688</PMID>
  </reference>
  <reference>
    <citation>Raymond J, Fahed R, Darsaut TE. Randomize the first patient. J Neuroradiol. 2017 Sep;44(5):291-294. doi: 10.1016/j.neurad.2017.03.004. Epub 2017 May 3.</citation>
    <PMID>28478113</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 20, 2018</study_first_submitted>
  <study_first_submitted_qc>September 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2018</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>brain arteriovenous malformation</keyword>
  <keyword>Arteriovenous malformations</keyword>
  <keyword>AVM</keyword>
  <keyword>BAVM</keyword>
  <keyword>stroke</keyword>
  <keyword>intracranial hemorrhage</keyword>
  <keyword>congenital abnormalities</keyword>
  <keyword>aneurysm</keyword>
  <keyword>vascular malformations</keyword>
  <keyword>cardiovascular abnormalities</keyword>
  <keyword>cardiovascular diseases</keyword>
  <keyword>vascular diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangioma</mesh_term>
    <mesh_term>Intracranial Arteriovenous Malformations</mesh_term>
    <mesh_term>Arteriovenous Malformations</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

